Company Filing History:
Years Active: 2023
Title: Innovations by James Qun Xue in Esophageal Cancer Treatment
Introduction
James Qun Xue is a notable inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the treatment of esophageal cancer. His innovative approach focuses on predicting patient responses to specific therapies, which can greatly enhance treatment efficacy.
Latest Patents
James Qun Xue holds a patent for a method that predicts the response of esophageal cancer to anti-ERBB3 antibody therapy. This patent, titled "Method for predicting response of esophagus cancer to anti-ERBB3 antibody therapy, and kit," discloses a method for determining whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor. The method involves measuring the expression of specific biomarkers at the RNA or protein level in tumor samples.
Career Highlights
James Qun Xue is currently associated with Canbridge Life Sciences Ltd. His work at this company emphasizes the importance of personalized medicine in oncology. His research aims to improve patient outcomes by tailoring treatments based on individual biomarker profiles.
Collaborations
James collaborates with esteemed colleagues, including Jing Wang and Ya Gao. Their combined expertise contributes to advancing cancer treatment methodologies and enhancing the understanding of esophageal cancer.
Conclusion
James Qun Xue's innovative work in predicting treatment responses for esophageal cancer represents a significant advancement in personalized medicine. His contributions are poised to make a lasting impact on cancer therapy and patient care.